Evaluating the potential of factor XI/factor XIa inhibitors to address unmet anticoagulation needs in critical...

Factor [F]XI/XIa inhibitors have emerged as a promising class of investigational anticoagulants that aim to preserve hemostasis while attenuating thrombosis. By selectively targeting the intrinsic pathway, FXI/XIa inhibition may provide effective antithrombotic protection with a lower risk of bleeding compared with conventional therapies. Early clinical studies across a range of indications suggest that FXI/XIa inhibition is associated with favorable safety profiles and predictable pharmacokinetics. Ongoing phase 3 trials are still evaluating the role of FXI/XIa inhibitors in multiple settings. If efficacy and safety are confirmed in larger studies, FXI/XIa inhibitors may represent an evolution in anticoagulant therapy, potentially expanding access to effective thromboprophylaxis for patients currently underserved by existing options. Continued investigation will be essential to define optimal dosing strategies, identify patient populations most likely to benefit, and establish how these agents integrate into evolving standards of care.